Transform osteomyelitis in diabetic foot
Courtesy of Courtesy of Mr Robert Morley, Specialist Registrar in Podiatric Surgery
67-year-old male patient with Type 2 diabetes presented with a 1 year history of a right foot ulcer and symptoms of infection with osteomyelitis caused by Staphylococcus aureus.Previous treatment involved 9 months I.V. antibiotics and regular re-dressing with no improvement. Most oral antibiotics were contraindicated due to a history of Clostridium difficile.
After surgical debridement and thorough irrigation, STIMULAN mixed with gentamicin and vancomycin was placed in the wound site. A 3 day perioperative course of I.V. antibiotic therapy was administered based on a bone biopsy with no other antibiotics used post-operatively.
5 weeks post-surgery the surgical wound and ulcer had healed and erythema and swelling had fully reduced. ESR and CRP were within normal limits and x-rays showed no deterioration. At 3 months the patient was mobilising normally, free from infection and the STIMULAN had fully absorbed. Implantation of STIMULAN negated the need to perform a full forefoot amputation.
For indications, contraindications, warnings and precautions see Instructions for Use. The treating physician is responsible for deciding the type and quantity of antibiotic used. Concurrent use of locally administered antibiotics may affect setting time.
The mixing of antibiotics with the STIMULAN Kit / STIMULAN Rapid Cure device is considered off-label usage of the medicinal product. To do so is at the professional risk of the surgeon / healthcare professional.
This page may include the use of STIMULAN or techniques that go beyond the current clearance/ approval granted by the relevant regulatory authority. Please contact your local representative for further information.
©2018, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.
Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1
Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, US 15/288328, GB1704688.9, EP 18275044.8, US 15/933936